Allogene Therapeutics Company Leadership
| ALLO Stock | USD 3.04 0.33 9.79% |
About 67% of Allogene Therapeutics' corporate insiders are selling. The analysis of the overall insider sentiment regarding Allogene Therapeutics suggests that many insiders are alarmed. Allogene Therapeutics employs about 232 people. The company is managed by 24 executives with a total tenure of roughly 60 years, averaging almost 2.0 years of service per executive, having 9.67 employees per reported executive.
| David Chang CEO President CEO, Co-Founder, Director |
| Arie Belldegrun Chairman Executive Chairman of the Board, Co-Founder |
Allogene Therapeutics' Insider Buying Vs Selling
33
Selling | Buying |
Latest Trades
| 2024-01-30 | Geoffrey M Parker | Acquired 190 @ 3.6 | View | ||
| 2023-12-18 | Deborah M Messemer | Disposed 18640 @ 2.7 | View | ||
| 2023-08-07 | Stephen Mayo | Disposed 10000 @ 4.29 | View |
Monitoring Allogene Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Allogene |
Allogene Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Allogene Therapeutics' future performance. Based on our forecasts, it is anticipated that Allogene will maintain a workforce of about 230 employees by May 2024.Allogene Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2684) % which means that it has lost $0.2684 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5551) %, meaning that it created substantial loss on money invested by shareholders. Allogene Therapeutics' management efficiency ratios could be used to measure how well Allogene Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to drop to -0.53. In addition to that, Return On Capital Employed is likely to drop to -0.55. At this time, Allogene Therapeutics' Total Assets are very stable compared to the past year. As of the 24th of April 2024, Non Current Assets Total is likely to grow to about 245.6 M, while Net Tangible Assets are likely to drop about 732.1 M.As of the 24th of April 2024, Common Stock Shares Outstanding is likely to drop to about 125.7 M. In addition to that, Net Loss is likely to drop to about (314.3 M)
Allogene Therapeutics Workforce Comparison
Allogene Therapeutics is rated below average in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 5,174. Allogene Therapeutics holds roughly 232 in number of employees claiming about 4% of equities under Health Care industry.
Allogene Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Allogene Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Allogene Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Allogene Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2023-12-01 | 3.0 | 3 | 1 | 1,740,000 | 18,640 |
| 2023-09-01 | 0.8333 | 5 | 6 | 1,447,249 | 205,245 |
| 2023-06-01 | 2.2 | 11 | 5 | 1,728,704 | 145,829 |
| 2023-03-01 | 1.8333 | 11 | 6 | 8,949,062 | 96,198 |
| 2022-12-01 | 0.3333 | 1 | 3 | 19,120 | 23,034 |
| 2022-09-01 | 0.25 | 1 | 4 | 35,328 | 19,000 |
| 2022-06-01 | 2.0 | 6 | 3 | 288,120 | 23,500 |
| 2022-03-01 | 1.1111 | 10 | 9 | 10,430,952 | 31,922,732 |
| 2021-09-01 | 0.5455 | 6 | 11 | 129,439 | 48,000 |
| 2021-06-01 | 0.8571 | 12 | 14 | 735,933 | 981,342 |
| 2021-03-01 | 1.0 | 13 | 13 | 1,098,510 | 94,151 |
| 2020-12-01 | 0.36 | 9 | 25 | 217,292 | 358,761 |
| 2020-09-01 | 0.2667 | 4 | 15 | 288,229 | 1,154,004 |
| 2020-06-01 | 0.4286 | 9 | 21 | 219,353 | 1,977,500 |
| 2020-03-01 | 2.0 | 12 | 6 | 1,823,898 | 266,690 |
| 2019-12-01 | 6.0 | 6 | 1 | 54,020 | 446,623 |
| 2019-09-01 | 1.5833 | 19 | 12 | 456,454 | 195,308 |
| 2019-06-01 | 1.5714 | 11 | 7 | 221,934 | 3,242,099 |
| 2018-12-01 | 1.0 | 17 | 17 | 53,277,981 | 31,963,723 |
Allogene Therapeutics Notable Stakeholders
An Allogene Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Allogene Therapeutics often face trade-offs trying to please all of them. Allogene Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Allogene Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| David Chang | President CEO, Co-Founder, Director | Profile | |
| Arie Belldegrun | Executive Chairman of the Board, Co-Founder | Profile | |
| MD FACS | CoFounder Chairman | Profile | |
| Geoffrey Parker | Executive CFO | Profile | |
| John DeYoung | Independent Director | Profile | |
| Franz Humer | Independent Director | Profile | |
| Joshua Kazam | Co-Founder, Director | Profile | |
| David Bonderman | Independent Director | Profile | |
| Owen Witte | Independent Director | Profile | |
| Deborah Messemer | Independent Director | Profile | |
| Todd Sisitsky | Independent Director | Profile | |
| Timothy Moore | Executive Officer | Profile | |
| Rafael MD | Ex RD | Profile | |
| FACS FACS | CoFounder Chairman | Profile | |
| Susan Lundeen | Chief Officer | Profile | |
| Veer Bhavnagri | G Officer | Profile | |
| Earl Esq | General Officer | Profile | |
| Christine Cassiano | Chief Officer | Profile | |
| Yinlin Chen | Senior Finance | Profile | |
| Alison Moore | Chief Technical Officer | Profile | |
| David JD | Secretary | Profile | |
| Eric Schmidt | Chief Officer | Profile | |
| Stephen Cheng | Chief Officer | Profile | |
| Barbra Sasu | Chief Scientific Officer | Profile |
About Allogene Therapeutics Management Performance
The success or failure of an entity such as Allogene Therapeutics often depends on how effective the management is. Allogene Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Allogene management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Allogene management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.51) | (0.53) | |
| Return On Capital Employed | (0.52) | (0.55) | |
| Return On Assets | (0.51) | (0.53) | |
| Return On Equity | (0.64) | (0.67) |
The data published in Allogene Therapeutics' official financial statements usually reflect Allogene Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Allogene Therapeutics. For example, before you start analyzing numbers published by Allogene accountants, it's critical to develop an understanding of what Allogene Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Allogene Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Allogene Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Allogene Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Allogene Therapeutics. Please utilize our Beneish M Score to check the likelihood of Allogene Therapeutics' management manipulating its earnings.
Allogene Therapeutics Workforce Analysis
Traditionally, organizations such as Allogene Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Allogene Therapeutics within its industry.Allogene Therapeutics Manpower Efficiency
Return on Allogene Therapeutics Manpower
| Revenue Per Employee | 409 | |
| Revenue Per Executive | 4K | |
| Net Loss Per Employee | 1.4M | |
| Net Loss Per Executive | 13.6M | |
| Working Capital Per Employee | 1.8M | |
| Working Capital Per Executive | 17.6M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Allogene Stock analysis
When running Allogene Therapeutics' price analysis, check to measure Allogene Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allogene Therapeutics is operating at the current time. Most of Allogene Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allogene Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allogene Therapeutics' price. Additionally, you may evaluate how the addition of Allogene Therapeutics to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is Allogene Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.09) | Revenue Per Share 0.001 | Quarterly Revenue Growth (0.55) | Return On Assets (0.27) | Return On Equity (0.56) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.